Zymeworks Inc.
ZYME · XNASCIK 1937653fmd_0N4ZMY8JAEJ3N7HED8TP6Z9NAEManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2020 to Sep 30, 2026, 24 periods
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Total revenues | 39 | 27 | 412 | 76 | 76 | 106 |
| Research and development | 171 | 200 | 209 | 144 | 135 | 137 |
| Operating income | (187) | (216) | 131 | (138) | (137) | (93) |
| Other non-operating income (expense) | 2 | 1 | 1 | (1) | 1 | (1) |
| Income before taxes | (180) | (212) | 135 | (119) | (117) | (80) |
| Income tax expense | 0 | (1) | 11 | (1) | 6 | 1 |
| Net income from continuing operations | (181) | (212) | 124 | (119) | (123) | (81) |
| Net income | (181) | (212) | 124 | (119) | (123) | (81) |
| Net income to common shareholders | (181) | (212) | 124 | (119) | (123) | (81) |